Compound · clinical trials

Cisplatin clinical trials

Also listed in trial records as Cisplatin /m^2, Platinol, Platinol-AQ, Blastolem, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloroplatinum, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 515 trials in our China, USA, Spain, France, Canada, South Korea, Italy, Japan, Taiwan, Germany, Australia, Israel, Mexico, UK, Poland, Belgium, Brazil, Turkey, Netherlands, Austria, Czechia, India, Switzerland, Denmark, Singapore, Ireland, Portugal, Sweden, Norway and Egypt registers that name Cisplatin as an intervention. Synced 9 Nov 2026

515Current trials

279Recruiting now

231Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Cisplatin is named as an intervention in 515 current clinical trials in our China, USA, Spain, France, Canada, South Korea, Italy, Japan, Taiwan, Germany, Australia, Israel, Mexico, UK, Poland, Belgium, Brazil, Turkey, Netherlands, Austria, Czechia, India, Switzerland, Denmark, Singapore, Ireland, Portugal, Sweden, Norway and Egypt registers. 279 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is AstraZeneca (36). The most-studied condition is Nasopharyngeal Carcinoma. The EU clinical trials register (CTIS) separately lists 15 authorised or ongoing trials, 1 with a site in Ireland.

Where Cisplatin is approved

All regulators →

Of the three regulators tracked here, the first to approve Cisplatin was the US, on 19 Dec 1978.

USUnited States (FDA)

19 Dec 1978

Platinol-aq

NDA018057 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

No centralised EU authorisation (it may be authorised nationally)

First centralised authorisation

CACanada (Health Canada)

No new-drug Notice of Compliance since 1994

First new-drug NOC

3 EU orphan designations, most recently for treatment of malignant mesothelioma (29 Aug 2016, positive)

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Cisplatin

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$497k

22,154 prescriptions in 2025 · Cisplatin, Cisplatin, CISplatin

-48% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Cisplatin works

All drug targets →

Diseases it has been tested for in clinical trials, by furthest phase

AscitesPhase 3
DysphagiaPhase 3
Hodgkins lymphomaPhase 3
Pleural effusionPhase 3
AdenocarcinomaPhase 3
Adrenal cortex carcinomaPhase 3
Anal squamous cell carcinomaPhase 3
Anus cancerPhase 3
Atypical teratoid rhabdoid tumorPhase 3
Biliary tract cancerPhase 3

292 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL11359, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 5343, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Cisplatin

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 2 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Cisplatin

ATC code: L01XA01
ChEMBL: CHEMBL11359
DrugBank: DB00515
PubChem CID: 5460033
CAS number: 15663-27-1
FDA UNII: Q20Q21Q62J
Wikidata: Q412415
Wikipedia: Cisplatin

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting27954%
Not yet open5010%
Active, closed18235%
By invitation41%

Trials by phase

Phase 221341%
Phase 316933%
Phase 2/3377%
Phase 1357%
Phase 1/2306%
Not applicable163%
Phase 471%
Observational61%
Early Phase 120%

Clinical trials of Cisplatin

515 trials

Study	Phase	Status	Lead sponsor	Registers
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer NCT06457503 · Nasopharyngeal Cancer Recurrent	Phase 4	Recruiting	Coherus Oncology, Inc	USA, Canada
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. NCT07279935 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 4	Recruiting	AstraZeneca	China
A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer NCT07619235 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)	Phase 4	Recruiting	Xianglin Yuan	China
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors NCT02429687 · ClinicalTrials.gov ↗ · Ovarian Germ Cell Cancer, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Beihua Kong	China
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors NCT02429700 · ClinicalTrials.gov ↗ · Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Beihua Kong	China
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours NCT02582697 · ClinicalTrials.gov ↗ · Germ Cell Tumor	Phase 3	Recruiting	University of Sydney	Australia
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors NCT03067181 · ClinicalTrials.gov ↗ · Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor	Phase 3	Recruiting	Children's Oncology Group	India, Canada, Mexico, Japan, Australia, Israel
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) NCT03126916 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Israel
Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread NCT03534713 · ClinicalTrials.gov ↗ · Cervical Cancer TNM Staging Regional Lymph Nodes (N)	Phase 3	Recruiting	University Hospital, Toulouse	France
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence NCT03583710 · ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma	Phase 3	Recruiting	M.D. Anderson Cancer Center	Germany, France, Sweden, Poland
Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy NCT04019548 · ClinicalTrials.gov ↗ · Oropharyngeal Cancer	Phase 3	Recruiting	Jules Bordet Institute	Belgium
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma NCT04136886 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
Pantoprazole in Cisplatin Nephrotoxicity NCT04217512 · ClinicalTrials.gov ↗ · Oncology	Phase 3	Recruiting	Sherief Abd-Elsalam	Egypt
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) NCT04221035 · ClinicalTrials.gov ↗ · High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Australia, Israel
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) NCT04267848 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Norway, Mexico, Israel
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition NCT04436965 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nutrition Therapy	Phase 3	Recruiting	Sun Yat-sen University	China
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma NCT04437329 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Affiliated Cancer Hospital & Institute of Guangzhou Medical University	China
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) NCT04447352 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Krankenhaus Nordwest	Germany
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) NCT04574960 · ClinicalTrials.gov ↗ · Bladder Cancer, Bladder Urothelial Carcinoma	Phase 3	Recruiting	University Health Network, Toronto	Canada
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) NCT04807673 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) NCT05281471 · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer	Phase 3	Recruiting	Genelux Corporation	USA
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma NCT05302284 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, HER2-expressing	Phase 3	Recruiting	RemeGen Co., Ltd	China
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study NCT05342194 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) NCT05357846 · ClinicalTrials.gov ↗ · Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer	Phase 3	Recruiting	Sun Yat-sen University	China
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss NCT05382338 · Childhood Medulloblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Israel
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. NCT05487391 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd	China
Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma NCT05527470 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Wei Jiang	China
Personalized Medicine for Advanced Biliary Cancer Patients NCT05615818 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms	Phase 3	Recruiting	UNICANCER	France, Belgium
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer NCT05624996 · ClinicalTrials.gov ↗ · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada, Mexico
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer NCT05659381 · ClinicalTrials.gov ↗ · Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer	Phase 3	Recruiting	GOG Foundation	Mexico
Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy NCT05674305 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Fudan University	China
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer NCT05798819 · ClinicalTrials.gov ↗ · Persistent, Recurrent, or Metastatic Cervical Cancer	Phase 3	Recruiting	Guangzhou Gloria Biosciences Co., Ltd	China
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04) NCT05827523 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	National Cancer Center, Korea	South Korea
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC NCT05854849 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma NCT05919030 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Renmin Hospital of Wuhan University	China
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma NCT06008106 · ClinicalTrials.gov ↗ · Melanoma	Phase 3	Recruiting	Shanghai Kechow Pharma, Inc	China
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC NCT06102395 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab	Phase 3	Recruiting	Beijing Tongren Hospital	China
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581 · Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis	Phase 3	Recruiting	Eli Lilly and Company	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer NCT06156514 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer, Gemcitabine, Chemo-radiotherapy	Phase 3	Recruiting	National Institute of Cancerología	Mexico
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma NCT06172296 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response NCT06239727 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer NCT06282575 · Biliary Tract Cancer	Phase 3	Recruiting	Jazz Pharmaceuticals	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Israel
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) NCT06312137 · Non Small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. NCT06431633 · ClinicalTrials.gov ↗ · Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma	Phase 3	Recruiting	Fundación GECP	Spain
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277 · Advanced Non-small Cell Lung Cancer, HER2 Mutation	Phase 3	Recruiting	Bayer	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357 · Biliary Tract Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% NCT06561386 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647 · Non-squamous Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases NCT06699212 · Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Rakuten Medical, Inc	USA, China, Japan, Taiwan
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma NCT06706401 · ClinicalTrials.gov ↗ · Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer	Phase 3	Recruiting	Centre Leon Berard	France
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. NCT06749899 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer	Phase 3	Recruiting	Sun Yat-Sen University Cancer Center	China
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer NCT06793215 · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer	Phase 3	Recruiting	Hoffmann-La Roche	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Egypt
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs NCT06829459 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Recruiting	Shanghai JMT-Bio Inc	China
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) NCT06875310 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Mirati Therapeutics Inc	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） NCT06927986 · ClinicalTrials.gov ↗ · EGFR-mutated Locally Advanced or Metastatic NSCLC	Phase 3	Recruiting	CSPC Megalith Biopharmaceutical Co.,Ltd	China
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) NCT06952504 · Endometrial Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation NCT06956001 · ClinicalTrials.gov ↗ · EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 3	Recruiting	Allist Pharmaceuticals, Inc	China
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases NCT06970639 · ClinicalTrials.gov ↗ · NSCLC Patients With Brain Metastasis	Phase 3	Recruiting	Allist Pharmaceuticals, Inc	China
Omitting CTV for Primary Tumor in LS-SCLC NCT07008716 · ClinicalTrials.gov ↗ · SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect	Phase 3	Recruiting	Sun Yat-sen University	China
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC NCT07026474 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Universität des Saarlandes	Germany, Switzerland
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07043400 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	BeOne Medicines	UK, USA, China, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Brazil, Mexico, Japan, South Korea
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer NCT07061977 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Mexico, Israel
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study NCT07097142 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma NCT07118527 · ClinicalTrials.gov ↗ · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma NCT07125755 · ClinicalTrials.gov ↗ · Squamous Cell Cancer of Head and Neck (SCCHN)	Phase 3	Recruiting	Sun Yat-sen University	China
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer NCT07168200 · ClinicalTrials.gov ↗ · Advanced Cervical Cancer	Phase 3	Recruiting	Shanghai Shengdi Pharmaceutical Co., Ltd	China
Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma NCT07177443 · ClinicalTrials.gov ↗ · Locally Advanced Nasopharyngeal Carcinoma	Phase 3	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC NCT07178795 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) NCT07216703 · Cervical Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) NCT07229625 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer NCT07276399 · Squamous Cell Carcinoma of Head and Neck	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial NCT07340515 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 3	Recruiting	Man Hu	China
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma NCT07371611 · ClinicalTrials.gov ↗ · Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)	Phase 3	Recruiting	Qunxing Li,MD	China
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC NCT07459296 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 3	Recruiting	First Affiliated Hospital of Guangxi Medical University	China
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) NCT07566156 · Urothelial Cancer, Urinary Bladder Neoplasms	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	USA, Canada, South Korea, Taiwan
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) NCT07680790 · Non-Small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	USA, India, China, Germany, France, Spain, Italy, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer NCT07710885 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Recruiting	Taiho Pharmaceutical Co., Ltd	Japan, South Korea, Australia
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer NCT07802821 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd	China
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) NCT07829783 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Taiwan
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma NCT02265770 · Childhood Ependymoma	Phase 2/3	Recruiting	Centre Leon Berard	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer NCT04628767 · ClinicalTrials.gov ↗ · Renal Pelvis and Ureter Urothelial Carcinoma	Phase 2/3	Recruiting	National Cancer Institute (NCI)	Mexico
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC NCT05125055 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1	Phase 2/3	Recruiting	Shanghai Jiao Tong University School of Medicine	China
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers NCT05893888 · Oral Squamous Cell Carcinoma	Phase 2/3	Recruiting	Privo Technologies	USA
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence NCT06037980 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Cholangiocarcinoma	Phase 2/3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency NCT06095141 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma, Homologous Recombination Deficiency	Phase 2/3	Recruiting	Fudan University	China
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer NCT06123884 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2/3	Recruiting	Bio-Thera Solutions	China
Radiation Therapy in Unresectable Gall Bladder Cancer NCT06214572 · Gall Bladder Cancer	Phase 2/3	Recruiting	Tata Memorial Centre	India
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC NCT06288373 · ClinicalTrials.gov ↗ · Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy	Phase 2/3	Recruiting	Tongji Hospital	China
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors NCT06493552 · Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma	Phase 2/3	Recruiting	Vasgene Therapeutics, Inc	USA
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07005102 · Non-Squamous Non-Small Cell Lung Cancer, c-MET	Phase 2/3	Recruiting	AbbVie	USA, China, Spain, Italy, Belgium, Portugal, Canada, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion NCT07063745 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) NCT07100080 · Non-Small Cell Lung Cancer	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Norway, Canada, Mexico, Japan, South Korea, Taiwan, Singapore
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy NCT07106762 · Urothelial Cancer	Phase 2/3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Japan, Australia, Israel
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma NCT07129993 · Urothelial Cancer, Bladder Cancer	Phase 2/3	Recruiting	Daiichi Sankyo	USA, China, Germany, France, Italy, Austria, Japan
A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's NCT07528495 · Head and Neck Cancer	Phase 2/3	Recruiting	All India Institute of Medical Sciences	India
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) NCT07554456 · Esophageal Squamous Cell Carcinoma	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) NCT07642024 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer NCT07662395 · ClinicalTrials.gov ↗ · Double Blind	Phase 2/3	Recruiting	Sinocelltech Ltd	China
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery NCT02734537 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma	Phase 2	Recruiting	ECOG-ACRIN Cancer Research Group	Mexico
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% NCT03351842 · ClinicalTrials.gov ↗ · Chemotherapy, Adjuvant, Lung Adenocarcinoma, Stage I, Treatment	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients NCT04159818 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary NCT04325425 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinoma	Phase 2	Recruiting	Centre Hospitalier Universitaire Dijon	France
Pemetrexed, Cisplatin With Soft Tissue Sarcoma NCT04605770 · ClinicalTrials.gov ↗ · Sarcoma,Soft Tissue	Phase 2	Recruiting	Yonsei University	South Korea
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma NCT04671667 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico
Using ctDNA to Determine Therapies for Lung Cancer NCT04966663 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA	Phase 2	Recruiting	University Health Network, Toronto	Canada
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC NCT05011487 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer NCT05061550 · Non-small Cell Lung Cancer	Phase 2	Recruiting	AstraZeneca	Ireland, USA, France, Spain, Italy, Belgium, Portugal, Turkey, Canada, South Korea, Taiwan
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III NCT05076942 · ClinicalTrials.gov ↗ · Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases	Phase 2	Recruiting	University Medical Center Groningen	Netherlands
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer NCT05104788 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma NCT05173246 · ClinicalTrials.gov ↗ · Esophageal Small Cell Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma NCT05180097 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma	Phase 2	Recruiting	Canadian Cancer Trials Group	Canada, Australia
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma NCT05188859 · ClinicalTrials.gov ↗ · Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK NCT05266846 · ClinicalTrials.gov ↗ · ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy	Phase 2	Recruiting	Hunan Province Tumor Hospital	China
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) NCT05281406 · ClinicalTrials.gov ↗ · NSCLC Stage IIIB, NSCLC Stage IV	Phase 2	Recruiting	Goethe University	Germany
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. NCT05351788 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) NCT05489211 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer NCT05640791 · ClinicalTrials.gov ↗ · Resectable Biliary Tract Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949 · ClinicalTrials.gov ↗ · Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable	Phase 2	Recruiting	Beth Israel Deaconess Medical Center	Israel
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients NCT05821556 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Pancreas	Phase 2	Recruiting	National Cancer Institute, Naples	Spain, Italy
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients NCT05825443 · ClinicalTrials.gov ↗ · Immunotherapy, Chemotherapy	Phase 2	Recruiting	Nanfang Hospital, Southern Medical University	China
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial NCT05862168 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma	Phase 2	Recruiting	Weijia Fang, MD	China
Pembrolizumab in Locally Advanced Sinonasal Carcinoma NCT05925491 · ClinicalTrials.gov ↗ · Sinonasal Undifferentiated Carcinoma	Phase 2	Recruiting	Istituti Clinici Scientifici Maugeri SpA	Italy
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma NCT06019130 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms	Phase 2	Recruiting	German Society for Pediatric Oncology and Hematology GPOH gGmbH	Germany
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer NCT06029270 · ClinicalTrials.gov ↗ · Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Singapore, Australia
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC NCT06055738 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer	Phase 2	Recruiting	Tang-Du Hospital	China
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) NCT06064097 · ClinicalTrials.gov ↗ · Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Australia, Israel
Dose Escalation Using Hypoxia-adjusted Radiotherapy NCT06087614 · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Rajiv Gandhi Cancer Institute & Research Center, India	India
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma NCT06091124 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinoma of the Bladder, Bladder Cancer	Phase 2	Recruiting	RenJi Hospital	China
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC NCT06100497 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Beijing Tongren Hospital	China
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma NCT06140966 · ClinicalTrials.gov ↗ · Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy NCT06208826 · ClinicalTrials.gov ↗ · Head and Neck Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) NCT06255210 · ClinicalTrials.gov ↗ · Olfactory Neuroblastoma	Phase 2	Recruiting	Hongmeng Yu	China
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC NCT06288360 · ClinicalTrials.gov ↗ · Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative	Phase 2	Recruiting	Tongji Hospital	China
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer NCT06289062 · ClinicalTrials.gov ↗ · Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation	Phase 2	Recruiting	Tongji Hospital	China
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer NCT06289751 · ClinicalTrials.gov ↗ · Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy	Phase 2	Recruiting	Tongji Hospital	China
Serplulimab Combined With CCRT for LS-SCLC. NCT06295926 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	Peking Union Medical College Hospital	China
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma NCT06323239 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy NCT06375915 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Francesco De Cobelli	Italy
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) NCT06387056 · ClinicalTrials.gov ↗ · Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma NCT06440993 · ClinicalTrials.gov ↗ · Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA	Phase 2	Recruiting	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma NCT06446726 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan University	China
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer NCT06463665 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer	Phase 2	Recruiting	Genelux Corporation	USA
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL NCT06489808 · ClinicalTrials.gov ↗ · Relapsed/Refractory Large B-Cell Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations NCT06514027 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Recruiting	BeBetter Med Inc	China
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer NCT06532279 · ClinicalTrials.gov ↗ · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	NRG Oncology	Mexico
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607 · Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Germany, Italy, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC NCT06536868 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Recruiting	Second Hospital of Shanxi Medical University	China
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer NCT06591650 · ClinicalTrials.gov ↗ · Gallbladder Cancer Unresectable	Phase 2	Recruiting	Fudan University	China
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC NCT06601309 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma NCT06632717 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	National Taiwan University Hospital	Taiwan
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer NCT06659042 · ClinicalTrials.gov ↗ · Lung Cancer, Non-Small Cell	Phase 2	Recruiting	Shanghai Chest Hospital	China
Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. NCT06670911 · ClinicalTrials.gov ↗ · Persistent, Recurrent, or Metastatic Cervical Cancer	Phase 2	Recruiting	Instituto Nacional de Cancer, Brazil	Brazil
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma NCT06696742 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
A Study of GC101 TIL in Advanced Melanoma NCT06703398 · ClinicalTrials.gov ↗ · Melanoma	Phase 2	Recruiting	Shanghai Juncell Therapeutics	China
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer NCT06708858 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Phase 2	Recruiting	Dai, Guanghai	China
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma NCT06718205 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Zhengzhou University	China
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma NCT06721286 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC NCT06725498 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Beijing Tongren Hospital	China
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC NCT06752798 · ClinicalTrials.gov ↗ · Head and Neck Cancer Squamous Cell Carcinoma	Phase 2	Recruiting	Hunan Cancer Hospital	China
Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma NCT06764355 · ClinicalTrials.gov ↗ · ESCC, Total Neoadjuvant Treatment, Pathological Complete Response	Phase 2	Recruiting	National Taiwan University Hospital	Taiwan
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial NCT06770582 · ClinicalTrials.gov ↗ · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma. NCT06851247 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy NCT06868836 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma NCT06869213 · ClinicalTrials.gov ↗ · Esophageal Cancer (EsC)	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer NCT06869226 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
Probiotics in Advanced Urothelial Carcinoma NCT06904573 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma, Probiotics, Immunotherapy	Phase 2	Recruiting	Sun Yat-sen University	China
Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) NCT06911606 · ClinicalTrials.gov ↗ · SCLC, Limited Stage	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma NCT06924619 · ClinicalTrials.gov ↗ · Locally Advanced Thymoma	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer NCT06959082 · Head and Neck Cancer Squamous Cell Carcinoma	Phase 2	Recruiting	VSPharmTech Co.,Ltd	USA
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2) NCT06960577 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate	Phase 2	Recruiting	AstraZeneca	France, Spain, Italy, Netherlands, Canada, Brazil, Australia
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer NCT07001618 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma NCT07030140 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer	Phase 2	Recruiting	Jinbo Yue	China
MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma NCT07036380 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma	Phase 2	Recruiting	Centre Hospitalier Universitaire de Besancon	France
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma NCT07039162 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer	Phase 2	Recruiting	Ming-Yu Lien	China, Taiwan
Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions NCT07090525 · ClinicalTrials.gov ↗ · Overall Response Rate	Phase 2	Recruiting	Qingdao Central Hospital	China
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma NCT07099547 · ClinicalTrials.gov ↗ · Biliary Tract Carcinoma	Phase 2	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer NCT07104149 · ClinicalTrials.gov ↗ · Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy, ECOG Score of 0-1	Phase 2	Recruiting	The First Affiliated Hospital of Zhengzhou University	China
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] NCT07111546 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer NCT07122687 · ClinicalTrials.gov ↗ · Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer	Phase 2	Recruiting	Innovent Biologics (Suzhou) Co. Ltd	China
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma NCT07136519 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 2	Recruiting	Affiliated Hospital of Guangdong Medical University	China
Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin. NCT07188441 · ClinicalTrials.gov ↗ · GCT, Germ Cell Tumor, Central Malignant Germ Cell Tumor	Phase 2	Recruiting	Chengcheng Guo	China
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC NCT07232654 · ClinicalTrials.gov ↗ · LOCALLY ADVANCED CERVICAL CANCERS	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma NCT07234058 · ClinicalTrials.gov ↗ · Pleural Mesotheliomas	Phase 2	Recruiting	Intergroupe Francophone de Cancerologie Thoracique	France
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer NCT07241767 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma NCT07248956 · ClinicalTrials.gov ↗ · Hypopharyngeal Carcinoma	Phase 2	Recruiting	Eye & ENT Hospital of Fudan University	China
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC) NCT07263919 · ClinicalTrials.gov ↗ · Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Akeso	China
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors NCT07268040 · ClinicalTrials.gov ↗ · Malignant Solid Tumors	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC NCT07296705 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Cancer (MIBC)	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC NCT07325539 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] NCT07331155 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma NCT07336147 · ClinicalTrials.gov ↗ · Female	Phase 2	Recruiting	Chang Gung Memorial Hospital	Taiwan
Cosiporfin Sodium for Injection Photodynamic Therapy NCT07398339 · ClinicalTrials.gov ↗ · Biliary Tract Cancers (BTC)	Phase 2	Recruiting	Shanghai Guangsheng Biopharmaceutical Co., Ltd	China
Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery NCT07400302 · ClinicalTrials.gov ↗ · Mucosal Melanoma, PD-L1 Positive	Phase 2	Recruiting	The First Hospital of Jilin University	China
A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer NCT07457346 · ClinicalTrials.gov ↗ · Head and Neck Cancer Squamous Cell Carcinoma	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer NCT07481058 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Recruiting	Beijing Konruns Pharmaceutical Co., Ltd	China
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab NCT07486817 · ClinicalTrials.gov ↗ · Lung Cancer, Non-squamous, Non-small Cell	Phase 2	Recruiting	Boehringer Ingelheim	China, Germany, France, Spain, Japan, South Korea, Australia
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680 · Solid Tumors	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, USA, China, Germany, France, Spain, Italy, Belgium, Norway, Canada, Japan, South Korea
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07559045 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Recruiting	Second Affiliated Hospital of Zunyi Medical University	China
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer NCT07569679 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	Air Force Military Medical University, China	China
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study NCT07583511 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer NCT07583550 · ClinicalTrials.gov ↗ · Lung, Radiotherapy	Phase 2	Recruiting	Jiangmen Central Hospital	China
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07601737 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer	Phase 2	Recruiting	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) NCT07622186 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. NCT07638852 · ClinicalTrials.gov ↗ · TNBC, Triple Negative Breast Cancer, Brain Metastasases	Phase 2	Recruiting	Fudan University	China
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer NCT07646301 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasms, Locally Advanced	Phase 2	Recruiting	Sun Yat-sen University	China
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC NCT07647289 · ClinicalTrials.gov ↗ · Muscle-Invasive Bladder Cancer (MIBC)	Phase 2	Recruiting	Peking University Third Hospital	China
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants NCT07668154 · ClinicalTrials.gov ↗ · HNSCC	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764 · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	Bristol-Myers Squibb	UK, USA, China, Germany, France, Spain, Italy, Brazil, Australia
Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma NCT07699185 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Tongji Hospital	China
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma NCT07700667 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT07744126 · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	AbbVie	USA, China, Japan, Taiwan
Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer NCT07751055 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Recruiting	Sun Yat-sen University	China
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) NCT07793942 · ClinicalTrials.gov ↗ · Malignant Neoplam, Advanced Solid Tumors	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Switzerland, Canada
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer NCT07831993 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer NCT07876154 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer	Phase 2	Recruiting	Xijing Hospital	China
Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study NCT07906587 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) NCT04198766 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer	Phase 1/2	Recruiting	Inhibrx Biosciences, Inc	USA, South Korea, Taiwan, Singapore
Chemoradiotherapy in Unresectable Esophageal Cancer NCT04278287 · ClinicalTrials.gov ↗ · Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel	Phase 1/2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation NCT05410145 · KRAS P.G12C	Phase 1/2	Recruiting	D3 Bio (Wuxi) Co., Ltd	USA, China, Germany, France, Spain, Italy, Japan, South Korea, Australia
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) NCT05482893 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) NCT05749900 · ClinicalTrials.gov ↗ · HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer	Phase 1/2	Recruiting	Yonsei University	South Korea
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation NCT05789082 · Non-Small Cell Lung Cancer	Phase 1/2	Recruiting	Hoffmann-La Roche	UK, USA, China, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma NCT06157827 · ClinicalTrials.gov ↗ · Advanced Neuroendocrine Carcinoma	Phase 1/2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC NCT06162221 · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer	Phase 1/2	Recruiting	Revolution Medicines, Inc	USA, Germany, France, Spain, Italy, Netherlands, Denmark, Austria, Czechia, South Korea, Taiwan, Australia
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer NCT06173986 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer	Phase 1/2	Recruiting	Shanghai Chest Hospital	China
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC NCT06217757 · ClinicalTrials.gov ↗ · Lung Cancer, Extensive-stage Small-cell Lung Cancer	Phase 1/2	Recruiting	Sichuan University	China
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Spain, Italy, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer NCT06512051 · ClinicalTrials.gov ↗ · Advanced or Metastatic Non-small Cell Lung Cancer	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China, Australia
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations NCT06772623 · Non Small Cell Lung Carcinoma, c-MET	Phase 1/2	Recruiting	AbbVie	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Japan, Taiwan, Australia
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer NCT06859775 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma NCT06956716 · ClinicalTrials.gov ↗ · Advanced Intrahepatic Cholangiocarcinoma	Phase 1/2	Recruiting	Zhejiang University	China
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) NCT06996782 · Advanced or Metastatic Non-small Cell Lung Cancer	Phase 1/2	Recruiting	AstraZeneca	USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. NCT07258979 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Nasopharyngeal Carcinoma	Phase 1/2	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd	China
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors NCT07335497 · Locally Advanced / Metastatic Solid Tumors	Phase 1/2	Recruiting	Crescent Biopharma, Inc	Ireland, UK, USA, France, Spain, Italy, South Korea, Australia
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer NCT07392541 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma	Phase 1/2	Recruiting	Tongji Hospital	China
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors NCT07466160 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Mabwell (Shanghai) Bioscience Co., Ltd	China
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. NCT07559929 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 1/2	Recruiting	Hangzhou DAC Biotechnology Co., Ltd	China
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer NCT02889666 · ClinicalTrials.gov ↗ · Recurrent Non-small Cell Lung Cancer	Phase 1	Recruiting	Shanghai Jiao Tong University School of Medicine	China, Japan
A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, France, Spain, Switzerland, South Korea, Taiwan, Israel
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC NCT04686305 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 1	Recruiting	AstraZeneca	USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
AB122 Platform Study NCT04999761 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer	Phase 1	Recruiting	Taiho Pharmaceutical Co., Ltd	Japan
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer NCT05172245 · ClinicalTrials.gov ↗ · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary	Phase 1	Recruiting	National Cancer Institute (NCI)	Canada
A Study of ASP3082 in Adults With Advanced Solid Tumors NCT05382559 · Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China, France, Spain, Japan, South Korea, Israel
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 NCT05570422 · Cervical Cancer	Phase 1	Recruiting	Kortuc, Inc	UK, India
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma NCT05984342 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 1	Recruiting	Affiliated Cancer Hospital of Shantou University Medical College	China
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies NCT06181032 · ClinicalTrials.gov ↗ · Biliary Tract Malignancies	Phase 1	Recruiting	First Affiliated Hospital of Fujian Medical University	China
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors NCT06241456 · Advanced Solid Tumor	Phase 1	Recruiting	Fate Therapeutics	USA
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors NCT06384352 · Advanced Solid Tumors	Phase 1	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd	USA, China, Canada, Japan, Australia
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) NCT06551142 · Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	UK, USA, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Israel
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685 · Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer	Phase 1	Recruiting	Eli Lilly and Company	USA, Germany, France, Spain, Japan, South Korea
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors NCT06657144 · Metastatic Solid Tumor, Advanced Solid Tumor	Phase 1	Recruiting	Coherus Oncology, Inc	USA, China, Taiwan
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies NCT06839105 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor	Phase 1	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer NCT06900647 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer, Recurrent Breast Cancer	Phase 1	Recruiting	Sun Yat-sen University	China
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC NCT06969612 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 1	Recruiting	Peking University Cancer Hospital & Institute	China
A Study of LY4175408 in Participants With Advanced Cancer NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms	Phase 1	Recruiting	Eli Lilly and Company	USA, China, France, Spain, Japan, South Korea
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients NCT07119996 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer	Phase 1	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07219212 · Squamous Cell Carcinoma of Head and Neck	Phase 1	Recruiting	Johnson & Johnson Enterprise Innovation Inc	USA, France, Spain, Japan
Pathological Response After Neoadjuvant Treatment on NSCLC NCT05167487 · ClinicalTrials.gov ↗ · Stage IIIA Non-small Cell Lung Cancer	Observational	Recruiting	Fundación GECP	Spain
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma NCT06490003 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, DNA Methylation	Observational	Recruiting	City of Hope Medical Center	Japan
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma NCT06718257 · ClinicalTrials.gov ↗ · Cholangiocarcinoma	Observational	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study NCT07640048 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Observational	Recruiting	Peking Union Medical College Hospital	China
Radiation Therapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia in Advanced Cervical Cancer NCT03249519 · ClinicalTrials.gov ↗ · Cervical Cancer	Not applicable	Recruiting	University of Erlangen-Nürnberg Medical School	Germany
Low-Dose Weekly vs High-Dose Cisplatin NCT03649048 · ClinicalTrials.gov ↗ · Locally Advanced Head and Neck Squamous Cell Carcinoma	Not applicable	Recruiting	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Canada
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery NCT04016389 · ClinicalTrials.gov ↗ · Cervical Cancer	Not applicable	Recruiting	University Health Network, Toronto	Canada
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma NCT05352321 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Not applicable	Recruiting	Sun Yat-sen University	China
PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer NCT05406856 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasms, Locally Advanced Cervical Carcinoma	Not applicable	Recruiting	Leiden University Medical Center	Netherlands
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma NCT05494190 · ClinicalTrials.gov ↗ · Hypopharyngeal Carcinoma	Not applicable	Recruiting	Eye & ENT Hospital of Fudan University	China
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma NCT05717790 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma by AJCC V8 Stage	Not applicable	Recruiting	Fourth Affiliated Hospital of Guangxi Medical University	China
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer NCT05800054 · ClinicalTrials.gov ↗ · Esophageal Neoplasms, Adverse Drug Event	Not applicable	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study NCT05857631 · Cervical Cancer, Endometrial Cancer	Not applicable	Recruiting	Tata Memorial Centre	India
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer NCT06480864 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Not applicable	Recruiting	Yunpeng Liu	China
IMPT Dose Escalation for NSCLC (HyDose) NCT06484491 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Not applicable	Recruiting	University Medical Center Groningen	Netherlands
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers NCT06611345 · ClinicalTrials.gov ↗ · Biliary Tract Cancers (BTC)	Not applicable	Recruiting	Jiangsu Healthy Life Innovation Medical Technology Co., Ltd	China
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation NCT06942039 · ClinicalTrials.gov ↗ · CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor	Early Phase 1	Recruiting	C17 Council	Canada
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer NCT06931145 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer	Phase 4	Not yet open	Peking Union Medical College Hospital	China
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer NCT06704620 · ClinicalTrials.gov ↗ · Advanced and Metastatic NSCLC	Phase 3	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer NCT07383116 · ClinicalTrials.gov ↗ · Non Squamous Non-small Cell Lung Cancer	Phase 3	Not yet open	Shanghai Huaota Biopharmaceutical Co., Ltd	China
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. NCT07540390 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Not yet open	Sun Yat-sen University	China
A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer NCT07613567 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Carcinoma	Phase 3	Not yet open	Fujian Cancer Hospital	China
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma NCT07691515 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 3	Not yet open	Zhejiang Cancer Hospital	China
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC NCT07720193 · ClinicalTrials.gov ↗ · Advanced Extrapulmonary Neuroendocrine Carcinoma	Phase 3	Not yet open	Nanjing Leads Biolabs Co.,Ltd	China
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) NCT07783321 · Nasopharyngeal Carcinoma (NPC)	Phase 3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma NCT07833839 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinomas (NEC)	Phase 3	Not yet open	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer NCT07896005 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC NCT07897188 · ClinicalTrials.gov ↗ · EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive	Phase 3	Not yet open	Jiangsu Aosaikang Pharmaceutical Co., Ltd	China
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC NCT04890522 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Metastasis, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) NCT07739186 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 2/3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma NCT05132985 · ClinicalTrials.gov ↗ · NSCLC, EGF-R Positive Non-Small Cell Lung Cancer	Phase 2	Not yet open	Liaoning Cancer Hospital & Institute	China
Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer NCT05799469 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer	Phase 2	Not yet open	Chongqing University Cancer Hospital	China
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. NCT06295094 · ClinicalTrials.gov ↗ · Gastric Cancer, Chemotherapy, Adjuvant, Peritoneal Metastases	Phase 2	Not yet open	Odense University Hospital	Germany, France, Sweden, Denmark
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors NCT06446388 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 2	Not yet open	Qilu Pharmaceutical Co., Ltd	China
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC NCT06475755 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Anti Angiogenesis	Phase 2	Not yet open	Tang-Du Hospital	China
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA) NCT06510465 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	RenJi Hospital	China
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC NCT06699498 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer NCT06713057 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer	Phase 2	Not yet open	West China Hospital	China
The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC NCT06895369 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 2	Not yet open	Sir Run Run Shaw Hospital	China
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma NCT06903273 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Biliary Tract Cancer (BTC)	Phase 2	Not yet open	National Cheng-Kung University Hospital	Taiwan
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer NCT07088731 · ClinicalTrials.gov ↗ · Cervical Carcinoma	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma NCT07110558 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC)	Phase 2	Not yet open	Sun Yat-sen University	China
Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen NCT07137039 · ClinicalTrials.gov ↗ · Locally Advanced Hypopharyngeal Cancer	Phase 2	Not yet open	The First Affiliated Hospital of Xiamen University	China
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base NCT07145931 · ClinicalTrials.gov ↗ · Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy	Phase 2	Not yet open	Sun Yat-sen University	China
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC NCT07403435 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer NCT07407452 · ClinicalTrials.gov ↗ · Ovarian Cancers	Phase 2	Not yet open	Jiangsu Cancer Institute & Hospital	China
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma NCT07514793 · ClinicalTrials.gov ↗ · Mesothelioma	Phase 2	Not yet open	Fudan University	China
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 NCT07531979 · ClinicalTrials.gov ↗ · ESCC, Tislelizumab, Chemotherapy	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC NCT07618910 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Not yet open	Tang-Du Hospital	China
A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion NCT07649369 · ClinicalTrials.gov ↗ · Malignant Pleural Effusions (Mpe)	Phase 2	Not yet open	Shanghai Jeyou Pharmaceutical Co., Ltd	China
An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma NCT07709533 · ClinicalTrials.gov ↗ · Valid MeSH Conditions	Phase 2	Not yet open	Sun Yat-sen University	China
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer NCT07712094 · ClinicalTrials.gov ↗ · Neuroendocrine Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial NCT07775040 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Not yet open	Sichuan Cancer Hospital and Research Institute	China
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC NCT07776340 · ClinicalTrials.gov ↗ · HPV-unrelated Head and Neck Squamous Cell Carcinoma	Phase 2	Not yet open	Fudan University	China
A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma NCT07778368 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC)	Phase 2	Not yet open	Shanghai East Hospital	China
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma NCT07797881 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 2	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
Perioperative Adebrelimab for Locally Advanced Cervical Cancer NCT07811375 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer	Phase 2	Not yet open	Anhui Provincial Hospital	China
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma NCT07812467 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma NCT07824856 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases	Phase 2	Not yet open	Sun Yat-sen University	China
Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer NCT07828756 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer NCT07845916 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma NCT07856069 · ClinicalTrials.gov ↗ · Medulloblastoma	Phase 2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) NCT07871214 · Early-Stage Non-Small Cell Lung Cancer	Phase 2	Not yet open	Bristol-Myers Squibb	UK, USA, China, Germany, France, Spain, Italy, Poland, Canada, Japan, South Korea, Taiwan, Australia
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. NCT06136988 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Esophageal Squamous Carcinoma	Phase 1/2	Not yet open	CSPC ZhongQi Pharmaceutical Technology Co., Ltd	China
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors NCT06594874 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Advanced Solid Tumors	Phase 1	Not yet open	Jiangsu Hansoh Pharmaceutical Co., Ltd	China
Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies NCT07782346 · ClinicalTrials.gov ↗ · Advanced Solid Malignancies	Phase 1	Not yet open	National Health Research Institutes, Taiwan	China, Taiwan
Combining Chemoradiotherapy With Sintilimab in First-Line ICC NCT06447454 · ClinicalTrials.gov ↗ · ICC	Observational	Not yet open	Shanghai Zhongshan Hospital	China
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection NCT04762459 · ClinicalTrials.gov ↗ · Non-small Cell Lung Carcinoma	Phase 3	By invitation	Chinese Academy of Medical Sciences	China
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma NCT07312578 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	By invitation	Peking University	China
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC NCT07353294 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Lymph Node Metastasis	Phase 1	By invitation	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma NCT06048926 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Not applicable	By invitation	The First Affiliated Hospital with Nanjing Medical University	China
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors NCT02875314 · ClinicalTrials.gov ↗ · Medulloblastoma, Central Nervous System Embryonal Tumors	Phase 4	Active, closed	Parth Patel	Canada
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma NCT05689671 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Metastatic	Phase 4	Active, closed	Nikolaj Frost MD	Germany
A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma NCT06879691 · ClinicalTrials.gov ↗ · Head and Neck Cancer	Phase 4	Active, closed	Biotech Pharmaceutical Co., Ltd	China
Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma NCT00470223 · ClinicalTrials.gov ↗ · Sarcoma	Phase 3	Active, closed	UNICANCER	France
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT00588770 · ClinicalTrials.gov ↗ · Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer NCT01566240 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Active, closed	University College, London	India, Italy, Brazil, Mexico
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer NCT02170090 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Gall Bladder Carcinoma	Phase 3	Active, closed	Universitätsklinikum Hamburg-Eppendorf	Germany, Italy, Netherlands, Denmark, Austria, Australia
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) NCT02215265 · Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer	Phase 3	Active, closed	Lisette Nixon	Germany, France, Australia
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors NCT02375204 · Germ Cell Tumor, Teratoma, Choriocarcinoma	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Switzerland, Australia
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy NCT02445391 · ClinicalTrials.gov ↗ · Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma	Phase 3	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) NCT02453282 · Non-Small-Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA, Germany, France, Spain, Italy, Netherlands, Belgium, Switzerland, Canada, Japan, South Korea, Taiwan, Australia
The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT NCT02460887 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers NCT02466971 · ClinicalTrials.gov ↗ · Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer NCT02516241 · Urothelial Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) NCT02542293 · Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Sweden, Denmark, Poland, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Singapore, Israel
Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) NCT02998385 · ClinicalTrials.gov ↗ · HNSCC	Phase 3	Active, closed	Groupe Oncologie Radiotherapie Tete et Cou	France
Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) NCT02999087 · ClinicalTrials.gov ↗ · HNSCC	Phase 3	Active, closed	Groupe Oncologie Radiotherapie Tete et Cou	France
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) NCT03003962 · Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA, China, Netherlands, Poland, Turkey, South Korea, Taiwan, Australia
Paediatric Hepatic International Tumour Trial NCT03017326 · Hepatoblastoma, Carcinoma, Hepatocellular	Phase 3	Active, closed	University of Birmingham	Ireland, Germany, France, Spain, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Israel
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) NCT03043872 · Small Cell Lung Carcinoma Extensive Disease	Phase 3	Active, closed	AstraZeneca	USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Czechia, Turkey, Brazil, Japan, South Korea, Taiwan, Israel
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). NCT03164616 · Non Small Cell Lung Cancer NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, Poland, Brazil, Mexico, Japan, South Korea, Taiwan
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT NCT03340896 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 3	Active, closed	Groupe Oncologie Radiotherapie Tete et Cou	France
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) NCT03425643 · Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Egypt
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer NCT03456076 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Denmark, Poland, Austria, Turkey, Japan, South Korea, Taiwan, Australia, Israel, Egypt
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery NCT03533582 · ClinicalTrials.gov ↗ · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck NCT03576417 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 3	Active, closed	Groupe Oncologie Radiotherapie Tete et Cou	France
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer NCT03682068 · Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Spain, Italy, Poland, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC NCT03732677 · Muscle Invasive Bladder Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) NCT03765918 · Head and Neck Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, Germany, France, Spain, Belgium, Poland, Switzerland, Austria, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) NCT03772028 · Ovarian Cancer	Phase 3	Active, closed	The Netherlands Cancer Institute	Ireland, France, Italy, Netherlands, Sweden, Denmark
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer NCT03775265 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer NCT03800134 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) NCT03811002 · ClinicalTrials.gov ↗ · Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Japan, Egypt
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer NCT03811015 · ClinicalTrials.gov ↗ · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma NCT03840421 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases	Phase 3	Active, closed	Sun Yat-sen University	China
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma NCT03967977 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Active, closed	BeiGene	China, Taiwan
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer NCT04025879 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Canada, Brazil, Mexico, Japan, Taiwan, Australia
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer NCT04092283 · ClinicalTrials.gov ↗ · Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) NCT04116047 · Oropharyngeal Cancer	Phase 3	Active, closed	University of Birmingham	Ireland
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer NCT04194944 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Eli Lilly and Company	UK, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer NCT04223856 · Urothelial Cancer	Phase 3	Active, closed	Astellas Pharma Global Development, Inc	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Czechia, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) NCT04241185 · Urinary Bladder Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Portugal, Turkey, Japan, South Korea, Taiwan, Australia, Israel
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer NCT04351555 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) NCT04379635 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Active, closed	BeiGene	China
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma NCT04456322 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC NCT04550260 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	AstraZeneca	USA, China, France, Spain, Belgium, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer NCT04595565 · HER2-negative Breast Cancer, Triple Negative Breast Cancer	Phase 3	Active, closed	GBG Forschungs GmbH	Ireland, Germany, France, Spain, Belgium, Switzerland, Austria
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) NCT04634877 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Israel
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder NCT04658862 · Urinary Bladder Neoplasms	Phase 3	Active, closed	Janssen Research & Development, LLC	USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) NCT04700124 · Bladder Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Portugal, Canada, Japan, South Korea, Taiwan, Singapore, Australia, Israel
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma NCT04907370 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer NCT04982237 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Active, closed	Akeso	China
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations NCT05048797 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer NCT05116462 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Innovent Biologics (Suzhou) Co. Ltd	China
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers NCT05152147 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma	Phase 3	Active, closed	Jazz Pharmaceuticals	Ireland, UK, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) NCT05173987 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) NCT05224141 · Small Cell Lung Carcinoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer NCT05235516 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Carcinoma	Phase 3	Active, closed	Akeso	China
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment NCT05261399 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma NCT05294172 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Recurrent or Metastatic	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer NCT05502237 · Non-small Cell Lung Cancer	Phase 3	Active, closed	Gilead Sciences	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Israel
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) NCT05555732 · Metastatic Non Small Cell Lung Cancer	Phase 3	Active, closed	Daiichi Sankyo	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) NCT05587374 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer	Phase 3	Active, closed	Sun Yat-sen University	China
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations NCT05687266 · NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Sweden, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) NCT05722015 · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	USA, China, France, Spain, Poland, Turkey, Brazil, Japan, Taiwan
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) NCT05771480 · Biliary Tract Cancer	Phase 3	Active, closed	AstraZeneca	USA, Germany, France, Spain, Italy, Japan, South Korea, Singapore
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients NCT05870319 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 NCT05911295 · Urothelial Carcinoma	Phase 3	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Sweden, Czechia, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma NCT06022861 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	Shandong Boan Biotechnology Co., Ltd	China
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma NCT06097728 · Unresectable Pleural Mesothelioma	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment NCT06151574 · Lung Cancer, Non-squamous, Non-small Cell	Phase 3	Active, closed	Boehringer Ingelheim	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Austria, Norway, Portugal, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension NCT06212752 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Japan
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma NCT06230224 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma (B-NHL)	Phase 3	Active, closed	Regeneron Pharmaceuticals	Spain, Turkey, Brazil, South Korea, Taiwan, Singapore, Australia
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) NCT06382116 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT06417814 · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features NCT06564844 · Non-small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, Turkey, Canada, Brazil, Japan, Taiwan
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer NCT06632327 · ClinicalTrials.gov ↗ · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) NCT06687369 · ClinicalTrials.gov ↗ · Non Squamous Non Small Cell Lung Cancer	Phase 3	Active, closed	mAbxience Research S.L	Spain, Italy, Poland, Portugal, Turkey, Brazil, Japan, South Korea, Taiwan
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer NCT06711900 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) NCT06726265 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 3	Active, closed	Immutep S.A.S	Ireland, UK, USA, India, Germany, Spain, Italy, Belgium, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Australia
A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer NCT07881705 · ClinicalTrials.gov ↗ · Myelosuppression	Phase 3	Active, closed	Jiangsu Simcere Pharmaceutical Co., Ltd	China
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma NCT01924819 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2/3	Active, closed	Australasian Gastro-Intestinal Trials Group	Germany, France, Spain, Belgium, Czechia, Canada, Australia, Israel
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA NCT02135042 · ClinicalTrials.gov ↗ · EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7	Phase 2/3	Active, closed	NRG Oncology	China, Canada, Taiwan, Singapore, Australia
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients NCT02221999 · ClinicalTrials.gov ↗ · Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer	Phase 2/3	Active, closed	RenJi Hospital	China
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature NCT02641847 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, Breast Cancer	Phase 2/3	Active, closed	Fudan University	China
Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers NCT02867865 · Gall Bladder Cancers	Phase 2/3	Active, closed	Tata Memorial Hospital	India
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) NCT03178552 · Non-Small Cell Lung Cancer	Phase 2/3	Active, closed	Hoffmann-La Roche	USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer NCT03952585 · Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT04442022 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-cell Lymphoma	Phase 2/3	Active, closed	Karyopharm Therapeutics Inc	USA, China, Spain, Italy, Poland, Israel
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer NCT04559139 · ClinicalTrials.gov ↗ · Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8	Phase 2/3	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer NCT05050162 · Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma	Phase 2/3	Active, closed	NRG Oncology	Ireland, Switzerland, Canada, Mexico
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers NCT05063552 · ClinicalTrials.gov ↗ · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Mexico
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer NCT05800015 · Non-small Cell Lung Cancer	Phase 2/3	Active, closed	Regeneron Pharmaceuticals	USA, Turkey, Canada, Mexico, South Korea, Taiwan, Australia, Israel
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). NCT06105619 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2/3	Active, closed	Beijing Pearl Biotechnology Limited Liability Company	China
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer NCT06115499 · ClinicalTrials.gov ↗ · Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma	Phase 2/3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico, Egypt
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT06236438 · Non-Small Cell Lung Cancer	Phase 2/3	Active, closed	AbbVie	USA, France, Spain, Netherlands, Belgium, Turkey, Japan, Taiwan, Australia, Israel
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer NCT06783140 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation	Phase 2/3	Active, closed	University Health Network, Toronto	Canada
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery NCT01220583 · ClinicalTrials.gov ↗ · Head and Neck Cancer	Phase 2	Active, closed	Radiation Therapy Oncology Group	Canada, Mexico
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT01585805 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada, Israel
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma NCT01878617 · ClinicalTrials.gov ↗ · Medulloblastoma	Phase 2	Active, closed	St. Jude Children's Research Hospital	Canada, Australia
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer NCT01898494 · ClinicalTrials.gov ↗ · Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer NCT02151084 · ClinicalTrials.gov ↗ · Biliary Tract Carcinoma, Gallbladder Carcinoma	Phase 2	Active, closed	University Health Network, Toronto	Canada
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma NCT02436707 · ClinicalTrials.gov ↗ · Lymphoma	Phase 2	Active, closed	Canadian Cancer Trials Group	Canada
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas NCT02595424 · ClinicalTrials.gov ↗ · Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer NCT02632305 · ClinicalTrials.gov ↗ · Unresectable Biliary Tract Cancer	Phase 2	Active, closed	AHS Cancer Control Alberta	Canada
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer NCT02711553 · Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer	Phase 2	Active, closed	Eli Lilly and Company	UK, USA, China, Germany, France, Spain, Belgium, Sweden, Denmark, Austria, Czechia, Turkey, Mexico, South Korea, Taiwan, Australia
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma NCT02724579 · ClinicalTrials.gov ↗ · Medulloblastoma	Phase 2	Active, closed	Children's Oncology Group	Canada, Australia, Israel
Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma NCT03047265 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC NCT03410615 · ClinicalTrials.gov ↗ · Oropharyngeal Squamous Cell Carcinoma	Phase 2	Active, closed	Canadian Cancer Trials Group	Spain, Italy, Belgium, Canada
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors NCT03485209 · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, Germany, France, Spain, Italy, Canada
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread NCT03547973 · Metastatic Urothelial Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA, Germany, France, Spain, Italy, Turkey, Mexico, South Korea
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations NCT03609216 · ClinicalTrials.gov ↗ · Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma	Phase 2	Active, closed	Alliance for Clinical Trials in Oncology	Egypt
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) NCT03775486 · Non-small Cell Lung Cancer NSCLC	Phase 2	Active, closed	AstraZeneca	UK, USA, India, Netherlands, Belgium, Poland, Mexico, Japan, South Korea
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma NCT03822897 · ClinicalTrials.gov ↗ · Oropharyngeal Cancer	Phase 2	Active, closed	Canadian Cancer Trials Group	Canada
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma NCT03937843 · ClinicalTrials.gov ↗ · Seminoma, Testicular Cancer	Phase 2	Active, closed	Swiss Cancer Institute	Germany, Switzerland
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) NCT03944772 · Non-Small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, Spain, Italy, Netherlands, Sweden, Denmark, Norway, Japan, South Korea
Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer NCT03982485 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	RenJi Hospital	China
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial NCT04216290 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. NCT04229459 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Baruch Brenner	Israel
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China, Germany, Spain, Italy, Netherlands, Poland, Canada, Brazil, Japan, South Korea, Taiwan
Cisplatin+Pembrolizumab+RT in Vulvar Cancer NCT04430699 · ClinicalTrials.gov ↗ · Vulvar Cancer, Vulvar Squamous Cell Carcinoma	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer NCT04516616 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasm, Uterine Cervical Cancer, Cervical Cancer	Phase 2	Active, closed	Huazhong University of Science and Technology	China
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC NCT04630730 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 2	Active, closed	Swiss Cancer Institute	Switzerland
Study of AZD2811 + Durvalumab in ES-SCLC NCT04745689 · ClinicalTrials.gov ↗ · Small-Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, Spain, Poland, South Korea
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases NCT05012254 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer	Phase 2	Active, closed	Fundación GECP	Spain
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) NCT05186974 · Non-small Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA, Germany, France, Spain, Italy, Canada, South Korea, Taiwan, Australia
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer NCT05198830 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Israel
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC NCT05247684 · ClinicalTrials.gov ↗ · Resectable Non-small Cell Lung Cancer	Phase 2	Active, closed	Akeso	China
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC NCT05343325 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment	Phase 2	Active, closed	Fifth Affiliated Hospital, Sun Yat-Sen University	China
Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer NCT05406674 · ClinicalTrials.gov ↗ · FIGO Stage III Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Carcinoma	Phase 2	Active, closed	The Netherlands Cancer Institute	Netherlands
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) NCT05451043 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer	Phase 2	Active, closed	AHS Cancer Control Alberta	Canada
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma NCT05524168 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery NCT05594290 · ClinicalTrials.gov ↗ · Merkel Cell Carcinoma	Phase 2	Active, closed	Gruppo Oncologico del Nord-Ovest	Italy
Study of Novel Treatment Combinations in Patients With Lung Cancer NCT05633667 · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA, Turkey, Brazil, South Korea, Taiwan, Israel
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients NCT05751187 · ClinicalTrials.gov ↗ · Non-squamous NSCLC	Phase 2	Active, closed	Shanghai Chest Hospital	China
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC NCT05765825 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Active, closed	Sichuan University	China
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer NCT05775159 · Hepatocellular Carcinoma, Biliary Tract Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China, Spain, Italy, Japan, South Korea, Taiwan
Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy NCT05796089 · ClinicalTrials.gov ↗ · Extensive-Stage Small-Cell Lung Cancer	Phase 2	Active, closed	Trans Tasman Radiation Oncology Group	Australia
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma NCT05813626 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Zhejiang Cancer Hospital	China
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer	Phase 2	Active, closed	Taiho Oncology, Inc	USA, Germany, France, Spain
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer NCT05966194 · Oral Mucositis	Phase 2	Active, closed	EpicentRx, Inc	USA
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation NCT05975307 · ClinicalTrials.gov ↗ · Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy	Phase 2	Active, closed	Sun Yat-sen University	China
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS NCT06008093 · Carcinoma, Non-Small-Cell Lung	Phase 2	Active, closed	AstraZeneca	USA
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) NCT06009861 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma	Phase 2	Active, closed	Peking University Hospital of Stomatology	China
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC NCT06081673 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	China
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery NCT06161441 · Resectable Non-small Cell Lung Cancer	Phase 2	Active, closed	Regeneron Pharmaceuticals	USA, Germany, France, Spain, Italy, Turkey, South Korea, Taiwan, Australia
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations NCT06194448 · Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, China, Spain, Turkey, South Korea, Taiwan, Israel
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) NCT06225596 · Metastatic Urothelial Cancer	Phase 2	Active, closed	BicycleTx Limited	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Canada, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer NCT06247956 · ClinicalTrials.gov ↗ · Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer NCT06419673 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer NCT06465563 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer NCT06511726 · Cervical Cancer	Phase 2	Active, closed	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study NCT06715592 · ClinicalTrials.gov ↗ · Paget Disease of the Vulva, Vulva Cancer	Phase 2	Active, closed	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Italy
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) NCT06788912 · Lung Neoplasm Malignant	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Turkey
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) NCT06946797 · Non-Small Cell Lung Cancer	Phase 2	Active, closed	Bristol-Myers Squibb	USA, France, Italy, Poland, Brazil
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer NCT07005336 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	TJ Biopharma Co., Ltd	China
Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC NCT07711470 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer NCT03473743 · Urothelial Carcinoma	Phase 1/2	Active, closed	Janssen Research & Development, LLC	UK, USA, China, France, Spain, Italy, Belgium, Poland, Turkey, Brazil, South Korea, Taiwan
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Active, closed	Genmab	UK, USA, China, Germany, France, Spain, Italy, Denmark, South Korea, Taiwan, Israel
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors NCT04495296 · ClinicalTrials.gov ↗ · Advanced Cancer	Phase 1/2	Active, closed	Transcenta Therapeutics (Hangzhou) Co., Ltd	China
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) NCT04956640 · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms	Phase 1/2	Active, closed	Eli Lilly and Company	USA, France, Canada, Japan, South Korea, Australia
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors NCT05229497 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors	Phase 1/2	Active, closed	Akeso	China
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma NCT05784012 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 1/2	Active, closed	Grupo Español de Tratamiento de Tumores de Cabeza y Cuello	Spain
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation NCT06501625 · ClinicalTrials.gov ↗ · Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	Phase 1/2	Active, closed	Institut de Recherches Internationales Servier	Germany, France, Spain, Canada, Brazil, Japan, South Korea, Australia
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) NCT02817633 · Neoplasms	Phase 1	Active, closed	Tesaro, Inc	USA, Spain, South Korea, Egypt
A Study of LY3200882 in Participants With Solid Tumors NCT02937272 · Solid Tumor	Phase 1	Active, closed	Eli Lilly and Company	USA, Germany, France, Spain, Italy, Canada, Japan, Australia
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC NCT03819465 · Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Active, closed	AstraZeneca	USA, Spain, Belgium, Poland, Austria, South Korea, Taiwan
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers NCT04328844 · Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC	Phase 1	Active, closed	iOnctura	UK, Italy
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer NCT04491942 · ClinicalTrials.gov ↗ · Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma	Phase 1	Active, closed	National Cancer Institute (NCI)	Canada
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations NCT04521686 · Cholangiocarcinoma, Chondrosarcoma, Glioma	Phase 1	Active, closed	Eli Lilly and Company	USA, China, France, Spain, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) NCT04526691 · Advanced or Metastatic NSCLC	Phase 1	Active, closed	Daiichi Sankyo	USA, Spain, Italy, Japan, Taiwan
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC NCT04947241 · ClinicalTrials.gov ↗ · Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy	Phase 1	Active, closed	Fifth Affiliated Hospital, Sun Yat-Sen University	China
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors NCT05599984 · Advanced Solid Tumors	Phase 1	Active, closed	AbbVie	USA, China, Germany, France, Spain, Italy, Japan, South Korea, Australia, Israel
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors NCT06057038 · ClinicalTrials.gov ↗ · Malignant Solid Tumor	Phase 1	Active, closed	Genmab	Japan
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers NCT06132113 · Neuroendocrine Neoplasms	Phase 1	Active, closed	Boehringer Ingelheim	USA, Germany, France, Spain, Netherlands, Belgium, Sweden, Japan
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA, Germany, France, Spain, Italy, Belgium, Japan, Taiwan
Investigating Cardiovascular Adverse Events Related to Cancer Treatment NCT03199300 · ClinicalTrials.gov ↗ · Toxicity Due to Chemotherapy, Cardiovascular Morbidity, Cancer, Treatment-Related	Observational	Active, closed	University Medical Center Groningen	Netherlands
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) NCT02194738 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8	Not applicable	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel
Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma NCT03306901 · ClinicalTrials.gov ↗ · Esophageal Cancer	Not applicable	Active, closed	Samsung Medical Center	South Korea
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma NCT04124198 · ClinicalTrials.gov ↗ · Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Carcinoma, Squamous Cell	Not applicable	Active, closed	Christian von Buchwald	Denmark
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma NCT04161248 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell	Early Phase 1	Active, closed	Canadian Cancer Trials Group	Canada

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Cisplatin in the EU trials register (CTIS)

15 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Cisplatin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors 2025-524623-50-00 · Neoplasms	Phase 1	Ongoing	Revolution Medicines Inc	Ireland + 8 more
A Phase III, Randomized, Open label Study of Izalontamab Brengitecan (Iza-bren/BMS-986507/BL-B01D1) in Combination with Osimertinib versus Osimertinib Monotherapy or Osimertinib in combination with Platinum-based Chemotherapy as First-Line Therapy in Patients with EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer 2026-526486-21-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Bristol-Myers Squibb Services Unlimited Company	Germany
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL‑M07D1) vs. Platinum-based Chemotherapy in Patients with HER2‑expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy 2026-527617-29-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Systimmune Inc	Germany, Bulgaria, France + 2 more
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations” 2026-525268-16-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Universita' Degli Studi Di Torino	Italy
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer with a High Tumor Burden (HighFive) [without IMPD-Q] 2026-525497-18-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	AIO-Studien gGmbH	Germany
IFEM – Pembrolizumab monotherapy versus pembrolizumab in combination with chemotherapy as first line therapy in females with advanced Non-small cell lung cancer (NSCLC) & PD-L1 expression ≥ 50% 2026-525387-18-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts	Germany
Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma 2026-525406-36-00 · Neoplasms	Phase 2	Authorised	Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia	Italy
A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP) 2025-523055-55-00 · Neoplasms	Phase 2	Authorised	Universitaetsklinikum Heidelberg AöR	Germany
COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial 2026-526122-41-00 · Not possible to specify	Phase 2	Authorised	Uppsala University Hospital	Sweden
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS) 2025-523599-21-00 · Neoplasms	Phase 2	Authorised	AstraZeneca AB	Spain, Germany
Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study 2025-521583-35-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Universita' Vita-salute S. Raffaele	Italy
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy 2025-521908-22-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Bristol-Myers Squibb Services Unlimited Company	Poland, Germany, Italy + 7 more
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 2025-522084-15-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	IRCCS Istituto Nazionale Tumori Fondazione Pascale	Italy
A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03). 2024-516906-47-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Daiichi Sankyo Inc	Netherlands, Germany, Norway + 8 more
A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4) 2025-521775-31-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Taiho Oncology Inc	Germany, Poland, Spain + 6 more

Cisplatin across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

2 single-substance products containing Cisplatin on the HPRA medicines list.

Cisplatin 1 mg/ml Concentrate for Solution for InfusionPfizer Healthcare Ireland Unlimited Company · PA0822/199/001 · Marketed
Cisplatin 1 mg/ml Concentrate for Solution for InfusionAccord Healthcare Ireland Ltd. · PA2315/081/001 · Marketed

All 2 Irish products →

Supply shortages

CisplatinEU (EMA) · Shortage resolved · first published 6 Aug 2024

EU shortages US shortages German shortages

Conditions studied with Cisplatin

513 conditions

Nasopharyngeal Carcinoma23 Non-Small Cell Lung Cancer22 Esophageal Squamous Cell Carcinoma17 Non-small Cell Lung Cancer16 Cervical Cancer15 Head and Neck Squamous Cell Carcinoma14 Carcinoma, Non-Small-Cell Lung13 Biliary Tract Cancer12 Cholangiocarcinoma8 Non Small Cell Lung Cancer7 Locally Advanced Cervical Cancer7 Bladder Cancer6

All 513 conditions

Condition (as registered)	Trials
Nasopharyngeal Carcinoma	23
Non-Small Cell Lung Cancer	22
Esophageal Squamous Cell Carcinoma	17
Non-small Cell Lung Cancer	16
Cervical Cancer	15
Head and Neck Squamous Cell Carcinoma	14
Carcinoma, Non-Small-Cell Lung	13
Biliary Tract Cancer	12
Cholangiocarcinoma	8
Non Small Cell Lung Cancer	7
Locally Advanced Cervical Cancer	7
Bladder Cancer	6
Esophageal Squamous Cell Carcinoma (ESCC)	6
Urothelial Cancer	5
Ovarian Cancer	5
Squamous Cell Carcinoma of Head and Neck	5
Lung Cancer	5
Gastric Cancer	5
Head and Neck Cancer	5
Advanced Solid Tumors	5
Advanced Solid Tumor	5
Nasopharyngeal Carcinoma (NPC)	5
Esophageal Cancer	5
Neoadjuvant Chemoimmunotherapy	5
Urothelial Carcinoma	4
Endometrial Neoplasms	4
Germ Cell Tumor	4
Colorectal Cancer	4
Pancreatic Ductal Adenocarcinoma	4
Urinary Bladder Neoplasms	4
Melanoma	4
Non-squamous Non-small Cell Lung Cancer	4
Solid Tumor	4
Head and Neck Cancer Squamous Cell Carcinoma	4
Oral Squamous Cell Carcinoma	4
Chemotherapy	4
Immunotherapy	4
Bladder Urothelial Carcinoma	4
Medulloblastoma	4
Neoadjuvant Therapy	4
Stage III Lung Cancer AJCC v8	4
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	4
Endometrial Cancer	3
Oropharyngeal Cancer	3
Gastroesophageal Junction Adenocarcinoma	3
Metastatic Urothelial Cancer	3
NSCLC	3
Metastatic Non-small Cell Lung Cancer	3
Neoplasm Metastasis	3
Ovarian Neoplasms	3
Recurrent Head and Neck Squamous Cell Carcinoma	3
Biliary Tract Cancer (BTC)	3
NSCLC (Advanced Non-small Cell Lung Cancer)	3
Locally Advanced Cervical Carcinoma	3
Small Cell Lung Cancer	3
Nasopharyngeal Cancer	3
Extensive-stage Small-cell Lung Cancer	3
Intrahepatic Cholangiocarcinoma (Icc)	3
Nasopharyngeal Cancinoma (NPC)	3
Breast Cancer	3
HNSCC	3
Oral Squamous Cell Carcinoma (OSCC)	3
Oropharyngeal Squamous Cell Carcinoma	3
Locally Advanced Head and Neck Squamous Cell Carcinoma	3
Stage II Lung Cancer AJCC v8	3
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	3
Small Cell Lung Carcinoma	2
Triple Negative Breast Cancer	2
Hepatoblastoma	2
Esophageal Adenocarcinoma	2
Colorectal Neoplasms	2
Hepatocellular Carcinoma	2
Non Small Cell Lung Carcinoma NSCLC	2
c-MET	2
Metastatic Non-Small Cell Lung Cancer (NSCLC)	2
Advanced Cancer	2
Lung Cancer, Non-squamous, Non-small Cell	2
Carcinoma	2
Malignant Solid Tumor	2
HER2-positive Gastric Cancer	2
Neoplasms	2
Muscle-Invasive Bladder Carcinoma	2
Locally Advanced or Metastatic Non-Small Cell Lung Cancer	2
Metastatic Solid Tumor	2
Resectable Non-small Cell Lung Cancer	2
Advanced or Metastatic Non-small Cell Lung Cancer	2
Pancreatic Cancer	2
Advanced Solid Tumour	2
Extensive-stage Small Cell Lung Cancer	2
Hypopharyngeal Carcinoma	2
Radiotherapy	2
Intrahepatic Cholangiocarcinoma	2
Pancreatic Adenocarcinoma	2
Bladder (Urothelial, Transitional Cell) Cancer	2
Metastatic Breast Cancer	2
Advanced Biliary Tract Carcinoma	2
SCLC, Limited Stage	2
Uterine Cervical Neoplasms	2
Bile Duct Cancer	2
Biliary Tract Cancers (BTC)	2
Lung Adenocarcinoma	2
Biliary Tract Carcinoma	2
ESCC	2
Chemotherapy, Adjuvant	2
Advanced Biliary Tract Cancer	2
Persistent, Recurrent, or Metastatic Cervical Cancer	2
Nasopharyngeal Neoplasms	2
Oropharynx Cancer	2
Resectable Lung Non-Small Cell Carcinoma	2
Vulvar Cancer	2
Lung Non-Squamous Non-Small Cell Carcinoma	2
Stage IIB Lung Cancer AJCC v8	2
Stage II Bladder Cancer AJCC v8	2
Stage IIIA Bladder Cancer AJCC v8	2
Ganglioneuroblastoma, Nodular	2
Neuroblastoma	2
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	2
Stage IV Nasopharyngeal Carcinoma AJCC v8	2
Stage IIIA Lung Cancer AJCC v8	2
Stage IIIB Lung Cancer AJCC v8	2
Recurrent Hypopharyngeal Squamous Cell Carcinoma	2
Recurrent Laryngeal Squamous Cell Carcinoma	2
Locally Advanced / Metastatic Solid Tumors	1
HER2-negative Breast Cancer	1
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Carcinoma, Hepatocellular	1
Gastric Neoplasms	1
Gastroesophageal Adenocarcinoma	1
Childhood Ependymoma	1
KRAS G12C Lung Cancer	1
Advanced Head and Neck Squamous Cell Carcinoma	1
Advanced Hypopharyngeal Squamous Cell Carcinoma	1
Advanced Laryngeal Squamous Cell Carcinoma	1
Advanced Oropharyngeal Squamous Cell Carcinoma	1
Solid Tumors	1
Teratoma	1
Choriocarcinoma	1
Germinoma	1
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)	1
Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)	1
Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
Exocrine Pancreatic Cancer	1
Carcinoma, Squamous Cell of Head and Neck	1
Carcinoma, Non-Small Cell Lung	1
HER2 Negative Breast Neoplasms	1
Unresectable Pleural Mesothelioma	1
Metastatic Gastric Adenocarcinoma	1
Muscle Invasive Bladder Cancer	1
Advanced Non-small Cell Lung Cancer, HER2 Mutation	1
Advanced or Metastatic Non-Small-Cell Lung Cancer	1
Resectable Non-Small-Cell Lung Cancer	1
Solid Tumor, Adult	1
Non-Hodgkin Lymphoma, Adult	1
Myelofibrosis	1
Non Small Cell Lung Carcinoma	1
Metastatic Non Small Cell Lung Cancer	1
Non-small Cell Lung Cancer NSCLC	1
Lung Neoplasms	1
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)	1
Metastatic Cancer	1
Non-Small-Cell Lung	1
Non-Small Cell Lung Cancer (NSCLC)	1
Colorectal Cancer (CRC)	1
Metastatic Castration-resistant Prostate Cancer	1
Metastatic Non-small Cell Lung Cancer With MTAP Deletion	1
Early-Stage Non-Small Cell Lung Cancer	1
Non Small Cell Lung Cancer NSCLC	1
Metastatic Urothelial Carcinoma	1
Unresectable Locally Advanced Urothelial Cancer	1
Advanced Non-squamous Non-small-cell Lung Cancer	1
Advanced Squamous Non-Small Cell Lung Carcinoma	1
Metastatic Non-squamous Non Small Cell Lung Cancer	1
Metastatic Squamous Non-Small Cell Lung Carcinoma	1
Non-Small-Cell Lung Carcinoma NSCLC	1
Non-Small Cell Lung Cancer, NSCLC	1
KRAS, NRAS, HRAS-mutated NSCLC	1
KRAS G12C-mutated Solid Tumors, Lung Cancer	1
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer	1
Non-Squamous Non-Small Cell Lung Cancer	1
Platinum-resistant Ovarian Cancer	1
Platinum-refractory Ovarian Cancer	1
Fallopian Tube Cancer	1
Primary Peritoneal Cancer	1
SMARCA4-Deficient Tumor	1
Advanced or Metastatic NSCLC	1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer	1
Esophageal Squamous Cell Cancer	1
Siewert Type 1 GEJ Cancer	1
Chondrosarcoma	1
Glioma	1
Any Solid Tumor	1
Oral Mucositis	1
Neuroendocrine Neoplasms	1
Lung Neoplasm Malignant	1
Relapsed/Refractory Diffuse Large B-cell Lymphoma	1
Nasopharyngeal Cancer Recurrent	1
Small-Cell Lung Cancer	1
Gastric or Gastroesophageal Junction Adenocarcinoma	1
KRAS P.G12C	1
Small Cell Lung Carcinoma Extensive Disease	1
Malignant Neoplam	1
Gall Bladder Cancers	1
Gall Bladder Cancer	1
Childhood Extracranial Germ Cell Tumor	1
Extragonadal Embryonal Carcinoma	1
Malignant Germ Cell Tumor	1
Advanced Malignant Tumors	1
EGFR	1
Cervical Carcinoma	1
Metastasis	1
Lymph Node Metastasis	1
Neuroendocrine Cancer	1
Lung Cancer, Non-Small Cell	1
Muscle-Invasive Bladder Cancer (MIBC)	1
Valid MeSH Conditions	1
Nasopharyngeal Carcinoma by AJCC V8 Stage	1
Advanced and Metastatic NSCLC	1
Non-small Cell Lung Carcinoma	1
Overall Response Rate	1
EGFR-mutated Locally Advanced or Metastatic NSCLC	1
Glioblastoma	1
Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma	1
Mucosal Melanoma	1
PD-L1 Positive	1
Programmed Cell Death Protein 1 Inhibitor	1
Squamous Cell Esophageal Carcinoma	1
Oesophageal Cancer	1
Ovarian Germ Cell Cancer	1
Locally Advanced Nasopharyngeal Carcinoma	1
Relapsed/Refractory Large B-Cell Lymphoma	1
Mesothelioma	1
Tubular Breast Cancer	1
Mucinous Breast Cancer	1
Invasive Ductal Breast Cancer	1
Inflammatory Breast Cancer	1
Double Blind	1
Concurrent Chemoradiotherapy	1
Female, Age ≥ 18 Years Old	1
No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy	1
ECOG Score of 0-1	1
Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion	1
Homologous Recombination Deficiency	1
Locally Advanced Unresectable Esophageal Cancer	1
Esophageal Small Cell Carcinoma	1
Recurrent Breast Cancer	1
Metastatic Gastric Cancer	1
Unresectable Gastric Carcinoma	1
Advanced Extrapulmonary Neuroendocrine Carcinoma	1
Nutrition Therapy	1
Non-squamous NSCLC	1
EGFR Activating Mutation	1
Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	1
MET Positive	1
Advanced Cervical Cancer	1
Skull Base--Cancer	1
Objective Response Rate	1
Advanced Urothelial Carcinoma	1
Probiotics	1
Myelosuppression	1
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor	1
Olfactory Neuroblastoma	1
Locally Advanced Prostate Cancer	1
Oligometastatic Prostate Cancer	1
Radiation Exposure	1
Radiotherapy Side Effect	1
Progression	1
Locally Advanced	1
PD-L1 Negative	1
Esophageal Cancer (EsC)	1
Gallbladder Cancer Unresectable	1
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma	1
Oropharyngeal Squamous Cell Carcinoma (OPSCC)	1
TNBC, Triple Negative Breast Cancer	1
Brain Metastasases	1
Chemoradiotherapy	1
Albumin-bound Paxlitaxel	1
Unresectable Malignant Neoplasm	1
Hilar Cholangiocarcinoma	1
Resectable Biliary Tract Cancer	1
Esophageal Neoplasms	1
Adverse Drug Event	1
EBV Infection	1
Stage II Nasopharyngeal Carcinoma AJCC v7	1
Stage III Nasopharyngeal Carcinoma AJCC v7	1
Stage IVA Nasopharyngeal Carcinoma AJCC v7	1
Unresectable Locally Advanced Esophageal Cancer	1
Mesothelioma, Malignant	1
Mesothelioma, Malignant Pleural	1
Mesothelioma Malignant Advanced	1
Advanced Solid Malignancies	1
Fertility Preservation	1
Locally Advanced Oral Squamous Cell Carcinoma	1
Anti Angiogenesis	1
EGF-R Positive Non-Small Cell Lung Cancer	1
Lung	1
GCT	1
Central Malignant Germ Cell Tumor	1
ALK Gene Mutation	1
Recurrent or Metastatic Nasopharyngeal Carcinoma	1
Biliary Tract Malignancies	1
Locally Advanced Unresectable Esophageal Squamous Carcinoma	1
Neuroendocrine Carcinoma of the Bladder	1
Radical Hysterectomy	1
Extrafascial Hysterectomy	1
Advanced Neuroendocrine Carcinoma	1
Advanced Intrahepatic Cholangiocarcinoma	1
Ovarian Sex Cord Stromal Tumor	1
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer	1
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	1
Locally Advanced Hypopharyngeal Cancer	1
Neoadjvant Therapy	1
Anti-PD-1	1
Muscle Invasive Bladder Cancer (MIBC)	1
Nasopharangeal Cancer	1
Locally Advanced Thyroid Gland Carcinoma	1
Thyroid Cancer	1
Uterine Cervical Neoplasm	1
Uterine Cervical Cancer	1
Malignant Solid Tumors	1
Non Squamous Non-small Cell Lung Cancer	1
Tislelizumab	1
Becotatug Vedotin	1
Malignant Pleural Effusions (Mpe)	1
Lung Adenocarcinoma, Stage I	1
Treatment	1
Histological Type of Neoplasm	1
Pembrolizumab	1
Neuroendocrine Carcinomas (NEC)	1
Recurrent or Metastatic Cervical Cancer	1
HER2-expressing	1
PD-L1	1
Anlotinib	1
NSCLC Patients With Brain Metastasis	1
Multiple Myeloma	1
Primary Plasma Cell Leukemia	1
Extramedullary Multiple Myeloma	1
Small-cell Lung Cancer	1
Nasopharyngeal Diseases	1
Head and Neck Neoplasm	1
ICC	1
Recurrent Non-small Cell Lung Cancer	1
LOCALLY ADVANCED CERVICAL CANCERS	1
Ovarian Cancers	1
Neoadjuvant Treatment	1
Squamous Cell Cancer of Head and Neck (SCCHN)	1
Recurrent or Metastatic	1
Head and Neck Squamous Cell Carcinoma (HNSCC)	1
Head & Neck Cancer	1
Lung Metastases	1
Liver Metastases	1
Locally Advanced Thymoma	1
HPV-unrelated Head and Neck Squamous Cell Carcinoma	1
Extrahepatic Cholangiocarcinoma	1
Unresectable Perihilar or Ductal CCA	1
NSCLC Stage IIIB	1
NSCLC Stage IV	1
Non-Small Cell Lung Cancer Metastatic	1
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	1
Nasopharynx Cancer	1
ENSAT Stage I Adrenal Cortex Carcinoma	1
ENSAT Stage II Adrenal Cortex Carcinoma	1
ENSAT Stage III Adrenal Cortex Carcinoma	1
Gall Bladder Carcinoma	1
Peritoneal Metastases	1
Minimally Invasive Surgical Procedures	1
Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer	1
Seminoma	1
Testicular Cancer	1
High-Risk Neuroblastoma	1
Patient With Insufficient Response Chemoimmunotherapy	1
Larynx Cancer	1
Hypopharynx Cancer	1
Primary Head and Neck Tumor	1
Neuroendocrine Carcinoma	1
Cervical Cancer TNM Staging Regional Lymph Nodes (N)	1
Pleural Mesotheliomas	1
Immune Checkpoint Inhibitors	1
Methotrexate	1
Vinblastine	1
Sarcoma	1
Biliary Tract Neoplasms	1
B-Cell Non-Hodgkin Lymphoma (B-NHL)	1
Stage IIIA Non-small Cell Lung Cancer	1
Non Squamous Non Small Cell Lung Cancer	1
Brain Metastases, Adult	1
Adenocarcinoma of the Pancreas	1
Lung Diseases	1
Sinonasal Undifferentiated Carcinoma	1
Merkel Cell Carcinoma	1
Paget Disease of the Vulva	1
Vulva Cancer	1
Toxicity Due to Chemotherapy	1
Cardiovascular Morbidity	1
Cancer, Treatment-Related	1
FIGO Stage III Ovarian Cancer	1
Peritoneal Cancer	1
Fallopian Tube Carcinoma	1
Sentinel Lymph Node	1
Lymph Node Metastases	1
Oropharynx Squamous Cell Carcinoma	1
Carcinoma, Squamous Cell	1
Lung Non-Small Cell Carcinoma	1
Lung Non-Small Cell Squamous Carcinoma	1
Limited Stage Lung Small Cell Carcinoma	1
Stage I Lung Cancer AJCC v8	1
Stage IB Lung Non-Small Cell Carcinoma AJCC v7	1
Stage II Lung Non-Small Cell Cancer AJCC v7	1
Stage IIA Lung Cancer AJCC v8	1
Muscle Invasive Bladder Carcinoma	1
Locally Advanced Pancreatic Adenocarcinoma	1
Metastatic Pancreatic Adenocarcinoma	1
Stage III Pancreatic Cancer AJCC v8	1
Stage IV Pancreatic Cancer AJCC v8	1
Locally Advanced Lung Non-Small Cell Carcinoma	1
Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Stage I Bladder Cancer AJCC v8	1
Lymphoma	1
Childhood Medulloblastoma	1
Ganglioneuroblastoma	1
Gallbladder Carcinoma	1
CNS Embryonal Tumor	1
CNS, Medulloblastoma	1
Atypical Teratoid Rhabdoid Tumor	1
Medulloblastoma, Childhood	1
Basaloid Squamous Cell Carcinoma	1
Hepatocellular Cancer	1
Advanced Vaginal Adenocarcinoma	1
Advanced Vaginal Adenosquamous Carcinoma	1
Advanced Vaginal Squamous Cell Carcinoma	1
Cervical Adenocarcinoma	1
Childhood Hepatocellular Carcinoma	1
Childhood Malignant Liver Neoplasm	1
Fibrolamellar Carcinoma	1
Advanced Bile Duct Carcinoma	1
Advanced Breast Carcinoma	1
Advanced Cervical Carcinoma	1
Advanced Endometrial Carcinoma	1
Hodgkin Lymphoma	1
Central Nervous System Embryonal Tumors	1
Pancreatic Cancer, Advanced or Metastatic	1
BRCA1/2 Mutation	1
PALB2 Gene Mutation	1
Metastatic Nasopharyngeal Carcinoma	1
Recurrent Nasopharyngeal Carcinoma	1
Stage II Nasopharyngeal Carcinoma AJCC v8	1
Stage III Nasopharyngeal Carcinoma AJCC v8	1
Muscle Invasive Bladder Urothelial Carcinoma	1
Complete Surgical Resection	1
Circulating Tumor DNA	1
Lymphoma, B-Cell	1
Head and Neck Carcinoma of Unknown Primary	1
Unresectable Biliary Tract Cancer	1
Stage III Ovarian Cancer	1
Stage IV Ovarian Cancer	1
Stage III Primary Peritoneal Cancer	1
Stage IV Primary Peritoneal Cancer	1
Stage III Bladder Cancer AJCC v8	1
Gemcitabine	1
Chemo-radiotherapy	1
Estrogen Receptor Negative	1
HER2/Neu Negative	1
Invasive Breast Carcinoma	1
Progesterone Receptor Negative	1
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	1
Metastatic Head and Neck Squamous Cell Carcinoma	1
Metastatic Hypopharyngeal Squamous Cell Carcinoma	1
Metastatic Laryngeal Squamous Cell Carcinoma	1
Pancreatic Acinar Cell Carcinoma	1
Pancreatic Adenosquamous Carcinoma	1
Pancreatic Carcinoma	1
Hypopharyngeal Squamous Cell Carcinoma	1
Laryngeal Squamous Cell Carcinoma	1
Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant	1
Human Papilloma Virus Infection	1
Stage III Squamous Cell Carcinoma of the Oropharynx	1
Stage IVA Squamous Cell Carcinoma of the Oropharynx	1
Stage IVB Squamous Cell Carcinoma of the Oropharynx	1
Recurrent Lung Non-Small Cell Carcinoma	1
Locally Advanced Cervical Adenocarcinoma	1
Locally Advanced Cervical Adenosquamous Carcinoma	1
Locally Advanced Cervical Squamous Cell Carcinoma	1
Stage IIIA Cervical Cancer FIGO 2018	1
Recurrent Oral Cavity Squamous Cell Carcinoma	1
Renal Pelvis and Ureter Urothelial Carcinoma	1
Gastric Neuroendocrine Carcinoma	1
Intestinal Neuroendocrine Carcinoma	1
Pancreatic Neuroendocrine Carcinoma	1
Stage II Gallbladder Cancer AJCC v8	1
Stage IIA Gallbladder Cancer AJCC v8	1
Stage IIB Gallbladder Cancer AJCC v8	1
Stage III Gallbladder Cancer AJCC v8	1
Neck Squamous Cell Carcinoma of Unknown Primary	1
Recurrent Laryngeal Verrucous Carcinoma	1
Advanced or Metastatic Solid Tumor	1
Chemotherapy Effect	1
DNA Methylation	1
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer	1
Sarcoma,Soft Tissue	1
Female	1
Total Neoadjuvant Treatment	1
Pathological Complete Response	1
Extensive-Stage Small-Cell Lung Cancer	1
Vulvar Squamous Cell Carcinoma	1
Cholangiocarcinoma Non-resectable	1
Cholangiocarcinoma Metastatic	1
Lung Large Cell Carcinoma	1
Oncology	1
Infiltrating Bladder Urothelial Carcinoma	1
Stage II Bladder Urothelial Carcinoma	1
Stage III Bladder Urothelial Carcinoma	1
Head and Neck Neoplasms	1

By country register

Register	Trials	Recruiting
Clinical trials in China	325	189
Clinical trials in USA	127	57
Clinical trials in Spain	117	46
Clinical trials in France	112	49
Clinical trials in Canada	106	47
Clinical trials in South Korea	103	43
Clinical trials in Italy	102	43
Clinical trials in Japan	99	44
Clinical trials in Taiwan	97	40
Clinical trials in Germany	93	38
Clinical trials in Australia	85	38
Clinical trials in Israel	70	25
Clinical trials in Mexico	70	25
Clinical trials in UK	69	29
Clinical trials in Poland	69	23
Clinical trials in Belgium	66	29
Clinical trials in Brazil	64	26
Clinical trials in Turkey	60	20
Clinical trials in Netherlands	57	27
Clinical trials in Austria	38	18
Clinical trials in Czechia	31	14
Clinical trials in India	31	18
Clinical trials in Switzerland	30	17
Clinical trials in Denmark	27	10
Clinical trials in Singapore	26	10
Clinical trials in Ireland	25	11
Clinical trials in Portugal	24	10
Clinical trials in Sweden	23	12
Clinical trials in Norway	20	10
Clinical trials in Egypt	9	2
EU register (CTIS)	15	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Cisplatin trials

How many clinical trials are testing Cisplatin?

515 current trials in our China, USA, Spain, France, Canada, South Korea, Italy, Japan, Taiwan, Germany, Australia, Israel, Mexico, UK, Poland, Belgium, Brazil, Turkey, Netherlands, Austria, Czechia, India, Switzerland, Denmark, Singapore, Ireland, Portugal, Sweden, Norway and Egypt registers name Cisplatin (also registered as Cisplatin /m^2) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Cisplatin trials recruiting patients?

Yes. 279 of the 515 trials are recruiting: 189 with sites in China, 57 with sites in USA, 46 with sites in Spain, 49 with sites in France, 47 with sites in Canada, 43 with sites in South Korea, 43 with sites in Italy, 44 with sites in Japan, 40 with sites in Taiwan, 38 with sites in Germany, 38 with sites in Australia, 25 with sites in Israel, 25 with sites in Mexico, 29 with sites in UK, 23 with sites in Poland, 29 with sites in Belgium, 26 with sites in Brazil, 20 with sites in Turkey, 27 with sites in Netherlands, 18 with sites in Austria, 14 with sites in Czechia, 18 with sites in India, 17 with sites in Switzerland, 10 with sites in Denmark, 10 with sites in Singapore, 11 with sites in Ireland, 10 with sites in Portugal, 12 with sites in Sweden, 10 with sites in Norway and 2 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Cisplatin clinical trials?

AstraZeneca (36), Sun Yat-sen University (32), National Cancer Institute (NCI) (22) and Merck Sharp & Dohme LLC (19), among 231 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Cisplatin clinical trials in Ireland?

Yes. 25 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Cisplatin licensed in Ireland?

Yes. The HPRA medicines list includes 2 single-substance products containing Cisplatin, for example Cisplatin 1 mg/ml Concentrate for Solution for Infusion (Pfizer Healthcare Ireland Unlimited Company). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Cisplatin shortage?

The registers we track list 1 entry for Cisplatin: Cisplatin (EU: shortage resolved). Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cisplatin works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cisplatin works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cisplatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.